Login
← Go Back
Bafna Pharmaceuticals
BAFNAPH · Pharma > Pharmaceuticals & Drugs · Chairman: Shanmugam Hemalatha Listing date: Nov. 13, 2012
Stock Price vs Company Growth
1d
2.0%
1w
10.2%
1m
48.2%
3m
105.1%
6m
236.3%
1y
209.0%
5y
28.7%
10y
30.8%
all
18.3%
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 478 2.0%
237
478
Company Overview
Sales
143 Cr
Growth: 3.8%
Profit after Tax
7.79 Cr
Growth: -29.9%
Small Cap
1,131 Cr
P/E: 224.4x
Industry P/E: 32.5x
Fundamentals
Sales (Cr) ₹ 143
Growth 3.8%
EBITDA 8.2%
P/S 7.9x
Dividend 0.0%
P/E 224.4x
Book Value ₹ 40.7
PEG Ratio 58.5x
ROE 8.3%
P/B 11.5x
Shareholding Pattern
Institutions
Promoters
Srjr Lifesciences Llp
90.0 %
Paras Bafna
0.21 %
Navin Bafna M
0.17 %
Amribai Bafna
0.01 %
Others
Monarch Networth Finserve Private Limited
1.4 %
Increase    Decrease    No change
Company Profile Detailed
:The company is engaged in the manufacturing of pharmaceutical products. It exports its products to the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries.Product Range:Anti-DiabeticCardiovascularAnti-HypertensiveBi-Layer AntihypertensiveAwards, accreditations and recognition1995: The company was awarded the WHO GMP.2005: The company bagged the ‘Best Supplier Award’ from the State Pharmaceutical Corporation of Sri Lanka.
Investors (55)
mahaveer...
paras.ba...
sasikala...